<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541836</url>
  </required_header>
  <id_info>
    <org_study_id>201901999A0</org_study_id>
    <nct_id>NCT04541836</nct_id>
  </id_info>
  <brief_title>Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy</brief_title>
  <official_title>Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will enroll 20 PSP and 8 normal subjects with complete neurological examination,&#xD;
      18F-PMPBB3 (APN-1607) PET and MRI assessment. To explore: (1) whether 18F-PMPBB3 (APN-1607)&#xD;
      can detect the 4R tau protein in the brain of PSP patients; (2) whether 18F-PMPBB3 (APN-1607)&#xD;
      can distinguish the clinical characteristics of PSP; (3) Whether the distribution of tau&#xD;
      deposition is related to disease severity, progression, and prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Progressive supranuclear palsy (PSP), also known as Steele-Richardson-Olszewski syndrome, has&#xD;
      a similar incidence in men and women. The pathophysiology of PSP is remaining unclear, but it&#xD;
      is known to be related to the abnormal accumulation of 4R tau protein in the brain. Recently,&#xD;
      new generation of novel radiotracer 18F-PMPBB3 (APN-1607), which can be labeled with 4R&#xD;
      PHF-tau without significant off-target binding, has been successfully developed. The study&#xD;
      will enroll 20 PSP and 8 normal subjects with complete neurological examination, 18F-PMPBB3&#xD;
      (APN-1607) PET and MRI assessment. To explore: (1) whether 18F-PMPBB3 (APN-1607) can detect&#xD;
      the 4R tau protein in the brain of PSP patients; (2) whether 18F-PMPBB3 (APN-1607) can&#xD;
      distinguish the clinical characteristics of PSP; (3) Whether the distribution of tau&#xD;
      deposition is related to disease severity, progression, and prognosis. The research results&#xD;
      will help to understand the potential of 18F-PMPBB3 (APN-1607) as a biomarker for diagnosis&#xD;
      and therapeutic assessment tool for progressive nuclear paralysis as well as other tau&#xD;
      proteinopathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tau Distribution Among Progressive Supranuclear Palsy (PSP), and Normal Subjects</measure>
    <time_frame>5 days</time_frame>
    <description>Tau Distribution Among Progressive Supranuclear Palsy (PSP), and Normal Subjects Measured by Standardized Uptake Value Ratio (SUVR) as Assessed by 18F-PM-PBB3 tau PET Scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess disease severity in PSP</measure>
    <time_frame>5 days</time_frame>
    <description>To assess disease severity in PSP subjects by SUVR as Assessed by 18F-PM-PBB3 tau PET Scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess disease progression in PSP</measure>
    <time_frame>1.5 year</time_frame>
    <description>To assess disease progression in PSP subjects by SUVR as Assessed by 18F-PM-PBB3 tau PET Scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3 hours</time_frame>
    <description>Systolic and diastolic pressure of subjects will be measured right before injection and after scanning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>3 hours</time_frame>
    <description>Pulse will be measured right before injection and after scanning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiration frequency</measure>
    <time_frame>3 hours</time_frame>
    <description>Respiration frequency will be measured right before injection and after scanning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>5 days</time_frame>
    <description>Adverse events within 5 days after the injection and scanning of subjects will be followed and assessed.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <description>healthy volunteer with no clinically relevant finding on physical examination at screening visit will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSP</arm_group_label>
    <description>Patients fulfill the criteria of NINDS-SPSP clinical criteria for the diagnosis of PSP &quot;as possible&quot; or &quot;probably&quot; PSP will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-PMPBB3</intervention_name>
    <description>single intravenous injection 5mCi 18F-PMPBB3 per scan</description>
    <arm_group_label>PSP</arm_group_label>
    <arm_group_label>healthy control</arm_group_label>
    <other_name>18F-APN-1607</other_name>
    <other_name>18F-MNI-958</other_name>
    <other_name>18F-APN-0000455</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        PSP patient will be enrolled from primary care clinic or hospital, control (healthy&#xD;
        subjects) will be enrolled from community.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          2. Patients fulfill the criteria of NINDS-SPSP clinical criteria for the diagnosis of PSP&#xD;
             &quot;as possible&quot; or &quot;probably&quot; PSP, and healthy volunteer with no clinically relevant&#xD;
             finding on physical examination at screening visit.&#xD;
&#xD;
          3. Age range 20-90 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Implantation of metal devices including cardiac pacemaker, intravascular metal&#xD;
             devices.&#xD;
&#xD;
          2. Major systemic diseases including coronary arterial disease, heart failure, uremia,&#xD;
             hepatic failure, prominent strokes, acute myocardial infarction, poorly controlled&#xD;
             diabetes, previous head injury, intracranial operation, hypoxia, sepsis or severe&#xD;
             infectious diseases&#xD;
&#xD;
          3. Major psychiatric disorders, drug or alcohol abuse and major depression&#xD;
&#xD;
          4. Pregnant women or breast- feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kun-Ju Lin, MD PhD</last_name>
    <phone>886-3-3281200</phone>
    <phone_ext>2625</phone_ext>
    <email>kunjulin@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital,Linkou</name>
      <address>
        <city>Taoyuan City</city>
        <state>Guishan Dist</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun-Ju Lin</last_name>
      <phone>03-3281200</phone>
      <phone_ext>2632</phone_ext>
      <email>kunjulin@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tauopathy</keyword>
  <keyword>Progressive Supranuclear Palsy</keyword>
  <keyword>F-18 APN1607 PET</keyword>
  <keyword>F-18 PMPBB3 PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

